Pan-filovirus immunoassay delivers reproducible serosurveillance results across US and DRC laboratories
Investigators evaluated a multiplex bead-based immunoassay for detecting humoral immunity to multiple filoviruses across two independent laboratories in Honolulu and Kinshasa, Democratic Republic of the Congo. Testing of 46 paired clinical samples and 907 longitudinal specimens from an ERVEBO vaccination campaign demonstrated high inter-laboratory correlation (r2=0.86-0.92) and coefficients of variation within predefined thresholds. The assay accurately tracked vaccine-induced EBOV glycoprotein antibody responses while showing minimal cross-reactivity to non-vaccine antigens. These findings confirm that the platform produces consistent results across distinct resource settings, making it a reliable tool for comparative serosurveillance and post-vaccination monitoring in filovirus-endemic regions.
The original study
Multiplex pan-filovirus assay performance and reproducibility across varied geographical and resource settings.
- Authors
- Smith OA, Merritt S, Kompany JP, Hoff NA, Wong TAS, Kamara V, et al.
- Journal
- PloS one
- Type
- Journal Article
- PMID
- 42623404
Original abstract
Multiplex bead-based immunoassays (MIAs) are promising tools for simultaneously detecting humoral immunity to multiple targets, potentially playing a crucial role in serosurveillance and vaccine response assessments. However, evaluation of assay performance is paramount prior to widespread use. This study presents a performance evaluation of a pan-filovirus MIA through characterization of the analytical range for the EBOV glycoprotein (GP) target and assessments of assay precision and antigen discrimination. The precision of the MIA was evaluated by comparing the detection of anti-filovirus antibodies at two independent laboratory sites: the University of Hawai'i, Honolulu (UH), and the Institut National de Recherche Biomédicale (INRB) in Kinshasa, Democratic Republic of the Congo (DRC). Forty-six samples from Yambuku, DRC, including Ebola virus Disease (EVD) survivors and close contacts, were tested at both sites. Additionally, 907 samples were tested in DRC before and after vaccination with a prophylactic EVD vaccine, ERVEBO. Results demonstrated low variability between laboratories, with intra-assay and inter-laboratory coefficients of variation below predefined thresholds for all filovirus targets included in the multiplex panel. Analyte correlation between sites was high (r2 = 0.86-0.92). Longitudinal analysis detected increased EBOV GP reactivity following vaccination, while reactivity to non-vaccine filovirus antigens remained stable, consistent with minimal cross-reactivity in a vaccinated cohort. These findings suggest that this pan-filovirus MIA produces reproducible results across distinct laboratory settings and may serve as a useful tool for comparative serologic investigations, serosurveillance, and evaluation of EBOV vaccine-associated antibody responses.